CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative DiseaseConstanze Slabik(Medizinische Hochschule Hannover), Renata Stripecke(University of Cologne)Molecular Therapy — OncolyticsAugust 8, 202010.1016/j.omto.2020.08.005Cited by 77SaveCiteExport RISWatch citationsRelated PapersDelta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET|Clinical Cancer Research|2020|25Supp Figure 2 from Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET|Unknown|2023|0Supp Figure 1 from Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET|Unknown|2023|0Supp Figure 4 from Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET|Unknown|2023|0Supp Figure 4 from Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET|Unknown|2023|0